0.00

100.00% -0.8307

After Hours: .84 0.84 +

Assertio Holdings Inc (ASRT)

Overview News Price History Option Chain Financials Why ASRT Down? Discussions Forecast Stock Split

Assertio Holdings Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Previous Close:

$0.8307

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$79.31M

Revenue:

$169.43M

Net Income/Loss:

$-186.01M

P/E Ratio:

0.00

EPS:

-2.02

Net Cash Flow:

$70.07M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

$0.9391

52-Week Range:

$0.00

$1.798

Assertio Holdings Inc Stock (ASRT) Company Profile

Name

Assertio Holdings Inc

Sector

Healthcare (8)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

(224) 419-7106

Address

100 S. SAUNDERS ROAD, LAKE FOREST, IL

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

ASRT's Discussions on Twitter

Compare ASRT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ASRT Assertio Holdings Inc	0.00	79.31M	169.43M	-186.01M	70.07M	-2.02

Assertio Holdings Inc Stock (ASRT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-26-24	Initiated	Maxim Group	Buy
Jul-03-24	Initiated	H.C. Wainwright	Buy
Nov-07-22	Initiated	Lake Street	Buy
Nov-30-18	Downgrade	Mizuho	Buy → Neutral

Assertio Holdings Inc Stock (ASRT) Latest News

Jan 03, 2025

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jan 03, 2025

Assertio Holdings Names New Chief Commercial Officer, Awards Major Stock Incentive Package - StockTitan

Jan 03, 2025

Jan 02, 2025

Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois against Assertio Holdings, Inc. - AccessWire

Jan 02, 2025

Dec 31, 2024

Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Up 14.1% in December - MarketBeat

Dec 31, 2024

Dec 24, 2024

Is Assertio Holdings (NASDAQ:ASRT) A Risky Investment? - Simply Wall St

Dec 24, 2024

Dec 18, 2024

Assertio appoints new independent director to board By Investing.com - Investing.com South Africa

Dec 18, 2024

Dec 17, 2024

Assertio appoints new independent director to board - Investing.com

Dec 17, 2024

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - The Manila Times

Dec 17, 2024

Assertio Holdings Taps Former Astellas President Who Led $5B Sales Growth to Join Board - StockTitan

Dec 17, 2024

Assertio’s (ASRT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Dec 17, 2024

Dec 16, 2024

Assertio Therapeutics shares get buy rating on clinical trial results By Investing.com - Investing.com Canada

Dec 16, 2024

Assertio (NASDAQ:ASRT) Receives Buy Rating from HC Wainwright - MarketBeat

Dec 16, 2024

Dec 15, 2024

Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Down 11.5% in November - MarketBeat

Dec 15, 2024

Dec 14, 2024

Assertio reports positive Rolvedon trial results for breast cancer By Investing.com - Investing.com Australia

Dec 14, 2024

Dec 13, 2024

Assertio Announces Results of Rolvedon (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study - Marketscreener.com

Dec 13, 2024

Assertio reports positive Rolvedon trial results for breast cancer - Investing.com

Dec 13, 2024

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - The Manila Times

Dec 13, 2024

Dec 12, 2024

Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO - The Manila Times

Dec 12, 2024

Assertio Holdings Creates Transformation Office, Appoints New Leadership to Drive Growth Strategy - StockTitan

Dec 12, 2024

Dec 06, 2024

Assertio Holdings Inc (NASDAQ: ASRT): Blank Check On Growth? - Stocks Register

Dec 06, 2024

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - GlobeNewswire Inc.

Dec 06, 2024

Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com

Dec 06, 2024

Nov 28, 2024

HC Wainwright Forecasts Stronger Earnings for Assertio - MarketBeat

Nov 28, 2024

Nov 25, 2024

Assertio shares hold price target, buy rating on stable Indocin share By Investing.com - Investing.com Canada

Nov 25, 2024

Assertio Holdings, Inc. (NASDAQ:ASRT) Shares Acquired by Empowered Funds LLC - Defense World

Nov 25, 2024

Nov 20, 2024

Assertio Holdings Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Assertio stock gains amid Q3 earnings, clash with activist investor - MSN

Nov 20, 2024

Nov 19, 2024

Insider Buying: Assertio Holdings, Inc. (NASDAQ:ASRT) Director Acquires $60,000.00 in Stock - MarketBeat

Nov 19, 2024

Assertio Holdings director Heather Mason buys $60,000 in shares By Investing.com - Investing.com Nigeria

Nov 19, 2024

Assertio Holdings director Heather Mason buys $60,000 in shares - Investing.com

Nov 19, 2024

Nov 15, 2024

Assertio Holdings CEO Brendan O'Grady buys $9,950 in common stock - Investing.com India

Nov 15, 2024

Spectrum Pharma Faces Senate Probe Call Over Alleged Rolvedon Data Fraud | ASRT Stock News - StockTitan

Nov 15, 2024

Nov 14, 2024